{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:40:21Z","timestamp":1792428021866,"version":"4.5.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Interstitial cystitis (IC) is a debilitating condition. Although viral infection is a potential etiological cause, few studies have detected the effect of antiviral treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the efficacy and safety of intravesical interferon instillation compared with hyaluronic acid in female patients with IC.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This double-masked, randomized phase 2\/3 clinical trial with parallel group design was implemented from October 2022 to April 2023 and had a 6-month follow-up period. The study was conducted at a single center. Eligible participants were female patients aged 18 to 70 years with a diagnosis of IC for more than 6 months. The last visit took place in October 2023. Data were analyzed between October and November 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Patients were randomized 1:1 to receive either intravesical instillation of interferon or hyaluronic acid.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was change in visual analog scale pain score. Secondary end points included changes in voiding frequency, functional bladder capacity, symptom index, and global response assessment. Adverse events were closely monitored.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 52 patients, the mean (SD) age was 50.0 (14.1) years and they were randomized to either the interferon group (26 [50%]) or hyaluronic acid (26 [50%]). The visual analog pain score showed the interferon group decreased more significantly than hyaluronic acid (\u22121.3; 95% CI, \u22122.3 to \u22120.3; P<\/jats:italic>\u2009=\u2009.02) at month 6, with 20 patients (77%) exhibiting a 30% or higher reduction in pain compared with baseline. Secondary end points of voiding frequency, functional bladder capacity, and nocturia episodes showed no significant difference between 2 therapies. However, interferon showed a significantly higher reduction in the Interstitial Cystitis Symptom Index (\u22123.0; 95% CI, \u22125.3 to \u22120.7; P<\/jats:italic>\u2009=\u2009.01) and the Problem Index (\u22122.5; 95% CI, \u22124.5 to \u22120.4; P<\/jats:italic>\u2009=\u2009.02) at month 6, with 22 patients (85%) presenting as moderately or markedly improved. The frequencies of adverse events were similar between 2 groups. Only 1 patient discontinued hyaluronic acid because of poor effectiveness.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, female patients with IC could benefit from intravesical interferon therapy, without serious adverse events. These results offered hope for antiviral approaches in IC, but larger-scale, multicenter trials and long-term follow-up should be considered.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT05912946<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.4880","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T15:01:16Z","timestamp":1712588476000},"page":"e244880","source":"Crossref","is-referenced-by-count":15,"title":["Intravesical Interferon Therapy vs Hyaluronic Acid for Pain Among Female Individuals With Interstitial Cystitis"],"prefix":"10.1001","volume":"7","author":[{"given":"Si-hong","family":"Shen","sequence":"first","affiliation":[{"name":"Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Peng","sequence":"additional","affiliation":[{"name":"Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[{"name":"Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"1","key":"zoi240207r1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","article-title":"Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal.","volume":"53","author":"van de Merwe","year":"2008","journal-title":"Eur Urol"},{"key":"zoi240207r2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejogrb.2013.12.041","article-title":"Interstitial cystitis\/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options.","volume":"175","author":"Davis","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"zoi240207r3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3109\/00365599.2012.669789","article-title":"Long-term experience with surgical treatment of selected patients with bladder pain syndrome\/interstitial cystitis.","volume":"46","author":"Andersen","year":"2012","journal-title":"Scand J Urol Nephrol"},{"issue":"4","key":"zoi240207r4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euf.2020.02.014","article-title":"A systematic review of surgical interventions for the treatment of bladder pain syndrome\/interstitial cystitis.","volume":"7","author":"Osman","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"10","key":"zoi240207r5","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.3390\/biomedicines10102380","article-title":"Current understanding of the pathophysiology and novel treatments of interstitial cystitis\/bladder pain syndrome.","volume":"10","author":"Jhang","year":"2022","journal-title":"Biomedicines"},{"key":"zoi240207r6","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.5213\/inj.2142100.050","article-title":"Improved urothelial cell proliferation, cytoskeleton and barrier function protein expression in the patients with interstitial cystitis\/bladder pain syndrome after intravesical platelet-rich plasma injection.","volume":"26","author":"Jhang","year":"2022","journal-title":"Int Neurourol J"},{"issue":"12","key":"zoi240207r7","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.3390\/diagnostics11122231","article-title":"Biomarkers in the light of the etiopathology of IC\/BPS.","volume":"11","author":"Neuhaus","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"zoi240207r8","doi-asserted-by":"publisher","first-page":"17258","DOI":"10.1038\/s41598-021-96810-w","article-title":"Difference in electron microscopic findings among interstitial cystitis\/bladder pain syndrome with distinct clinical and cystoscopic characteristics.","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"issue":"5-6","key":"zoi240207r9","doi-asserted-by":"publisher","first-page":"E136","DOI":"10.5489\/cuaj.3786","article-title":"CUA guideline: Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome.","volume":"10","author":"Cox","year":"2016","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"zoi240207r10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment.","volume":"193","author":"Hanno","year":"2015","journal-title":"J Urol"},{"issue":"2","key":"zoi240207r11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/nau.v38.2","article-title":"GAG replenishment therapy for bladder pain syndrome\/interstitial cystitis.","volume":"38","author":"Wyndaele","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"zoi240207r12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41392-022-00962-8","article-title":"Integrating single-cell RNA sequencing with spatial transcriptomics reveals immune landscape for interstitial cystitis.","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"zoi240207r13","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1086\/599387","article-title":"Decreased viral load and symptoms of polyomavirus-associated chronic interstitial cystitis after intravesical cidofovir treatment.","volume":"48","author":"Eisen","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi240207r14","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s11262-020-01767-z","article-title":"Analysis of viruses present in urine from patients with interstitial cystitis.","volume":"56","author":"Robles","year":"2020","journal-title":"Virus Genes"},{"issue":"8","key":"zoi240207r15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/v12080865","article-title":"Indoleamine 2,3-Dioxygenase is involved in interferon gamma\u2019s anti-BKPyV activity in renal cells.","volume":"12","author":"Fiore","year":"2020","journal-title":"Viruses"},{"issue":"10","key":"zoi240207r16","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3390\/v13101937","article-title":"IFNa and \u00df mediated JCPyV suppression through C\/EBP\u00df-LIP isoform.","volume":"13","author":"May","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"zoi240207r17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"issue":"5","key":"zoi240207r18","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00404-011-2124-2","article-title":"Lower urinary tract symptoms in primiparous women before and during pregnancy.","volume":"285","author":"Liang","year":"2012","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"zoi240207r19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.urology.2005.07.014","article-title":"Responsiveness of symptom scales for interstitial cystitis.","volume":"67","author":"Propert","year":"2006","journal-title":"Urology"},{"issue":"3","key":"zoi240207r20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/01.ju.0000083020.06212.3d","article-title":"A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis.","volume":"170","author":"Sant","year":"2003","journal-title":"J Urol"},{"issue":"6","key":"zoi240207r22","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1093\/ije\/dyac123","article-title":"Sample size calculators for planning stepped-wedge cluster randomized trials: a review and comparison.","volume":"51","author":"Ouyang","year":"2022","journal-title":"Int J Epidemiol"},{"issue":"4","key":"zoi240207r23","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1159\/000447863","article-title":"Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid\/chondroitin sulfate instillation for interstitial cystitis\/painful bladder syndrome.","volume":"39","author":"Pyo","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"zoi240207r24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.eururo.2018.07.026","article-title":"A randomized, double-blind, placebo-controlled trial of certolizumab pegol in women with refractory interstitial cystitis\/bladder pain syndrome.","volume":"74","author":"Bosch","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"zoi240207r25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/iju.2009.16.issue-1","article-title":"Japanese guideline for diagnosis and treatment of interstitial cystitis.","volume":"16","author":"Homma","year":"2009","journal-title":"Int J Urol"},{"key":"zoi240207r26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/iju.2019.26.issue-S1","article-title":"Phenotyping of interstitial cystitis\/bladder pain syndrome.","volume":"26","author":"Akiyama","year":"2019","journal-title":"Int J Urol"},{"key":"zoi240207r27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/iju.2019.26.issue-S1","article-title":"Hunner lesion versus non-Hunner lesion interstitial cystitis\/bladder pain syndrome.","volume":"26","author":"Whitmore","year":"2019","journal-title":"Int J Urol"},{"issue":"5","key":"zoi240207r28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/iju.v28.5","article-title":"Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis\/bladder pain syndrome in Japanese patients: a multicenter, randomized, double-blind, placebo-controlled, clinical study.","volume":"28","author":"Yoshimura","year":"2021","journal-title":"Int J Urol"},{"key":"zoi240207r21","unstructured":"PASS 2021 power analysis and sample size software. Accessed February 28, 2024. https:\/\/www.ncss.com\/software\/pass\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2817297\/shen_2024_oi_240207_1713798920.6618.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T15:01:32Z","timestamp":1714489292000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2817297"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.4880","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]}}}